LGALS3 and non-small cell lung carcinoma: In addition, it has also been shown in NSCLC models that inhibition of Gal-3 enhances the performance of immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1/programmed cell death 1 ligand (PD-1/PD-L1) axis (14, 15).